CLYM Climb Bio, Inc.
Price Chart
Executive Summary
Climb Bio entered into a new at-the-market (ATM) equity distribution agreement with Jefferies LLC for up to $100 million in common stock, replacing a prior undrawn ATM facility with Oppenheimer. The new facility represents potential dilution of ~16% of current market cap and signals ongoing cash needs for a pre-revenue biotech.
Actionable Insight
The new ATM creates persistent overhang; monitor periodic disclosures for actual sales. The termination of the prior undrawn facility is neutral. Watch for any pipeline catalysts that could offset dilution concerns.
Key Facts
- New ATM agreement with Jefferies LLC for up to $100 million of common stock
- Prior Oppenheimer ATM facility (up to $22.35 million) terminated with zero shares sold
- Jefferies will receive a 3% selling commission on gross proceeds
- The company is a pre-revenue clinical-stage biotech with $625 million market cap
Financial Impact
Potential dilution of up to 16% of current float if the full $100 million is sold at current prices
Risk Factors
- Potential staggered equity sales may pressure stock price
- Pre-revenue status with no near-term revenue catalysts
- Executive departure 4 days prior adds uncertainty
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-269567 |
| Document: d92589d8k.htm | 0001193125-26-269567 |
| Document: d92589dex51.htm | 0001193125-26-269567 |
| Document: 0001193125-26-269567-index-headers.html | 0001193125-26-269567 |
| Document: 0001193125-26-269567-index.html | 0001193125-26-269567 |
| Document: 0001193125-26-269567.txt | 0001193125-26-269567 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
8-K
| $11.44 awaiting T+5 | awaiting T+5 | — | $11.44 (+0.00%) |
|
Jun 12, 2026
2d ago
|
424B5
| $11.44 awaiting T+5 | awaiting T+5 | — | $11.44 (+0.00%) |
|
Jun 10, 2026
5d ago
|
EFFECT
| $11.14 awaiting T+5 | awaiting T+5 | — | $11.44 (+2.69%) |
|
Jun 5, 2026
9d ago
|
8-K
| $10.77 awaiting T+5 | awaiting T+5 | — | $11.44 (+6.22%) |
|
May 29, 2026
16d ago
|
S-3
| $11.80 $10.55 | ▼ −10.59% | ▼ −7.84% | $11.44 (−3.05%) |
|
May 7, 2026
5w ago
|
8-K
| $11.91 $11.41 | ▼ −4.20% | ▼ −5.70% | $11.44 (−3.95%) |
|
May 5, 2026
5w ago
|
8-K
| $11.45 $11.17 | ▼ −2.45% | ▼ −4.43% | $11.44 (−0.09%) |
|
Apr 28, 2026
6w ago
|
8-K
| $9.26 $9.69 | ▼ −4.64% | ▼ −2.95% | $11.44 (−23.54%) |
|
Apr 24, 2026
7w ago
|
DEFA14A
| $9.50 $9.69 | ▲ +2.00% | ▲ +1.60% | $11.44 (+20.42%) |
|
Apr 3, 2026
10w ago
|
8-K
| $6.74 $8.63 | ▲ +28.04% | ▲ +23.91% | $11.44 (+69.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access